The listing below shows our latest News Items and is updated regularly. If you wish to post a news item please select the 'Post News' button on the right. The displayed news feed starts on 1st August 2016. Older items can be found here.
To 'Post Your News' use the button at the top right.
We are pleased to present below all posts archived in 'February, 2019'. If you still can't find what you are looking for, try using the search box.
Good news! It’s finally here and has been rebranded as Smart Grants. If you’ve been working within the R&D funding world for as long as we have, you will know that a couple of years ago, ‘Smart’ was the name of the Open, so the name may induce a slight feeling of déjà vu!
Read the rest of entry »
AMSBIO has established a comprehensive portfolio of knock-out cell lines and lysates generated with CRISPR/Cas9 technology.
Using CRISPR/Cas9 gene editing technology for the generation of knock-out cell lines and cell lysates ensures the development of useful tools to validate antibody specificity and elucidate gene function. Knock-out cell lines and cell lysates are widely agreed to be the best negative controls to quickly and confidently prove an antibody’s specificity for a target of interest and ensure reproducibility.
Oxford, UK – February 12, 2019 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced that the first commercial production of Axumin® (fluciclovine (18F)) in Italy occurred recently, with the first Italian patients being dosed.
Arecor Ltd, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, is pleased to announce that the Company has been awarded a £0.5 million grant from Innovate UK, the UK’s innovation agency, to advance the Company's proprietary super-fast-acting prandial insulin product, AT270.
AMSBIO is a leading supplier of gold, silver and platinum coated substrates for nanotechnology researchers looking to use these surfaces to characterize self-assembled monolayers using atomic force microscopy (AFM), or scanning tunneling microscopy (STM).
Grey Wolf Therapeutics completes £10 million ($14 million) series A financing with Andera Partners and Canaan to fund development of immuno-oncology therapies to increase tumour visibility
BioCity, the UK’s largest life science incubator has been appointed by Newcastle City Council to run a life science accelerator and business support programme from The Biosphere, which is based on Newcastle Helix.
Earlier this month, Horton International (UK) launched its 2019 European Life Science Report, published following our annual survey among the movers and shakers within the European Life Science sector.
Cardiff, UK - CatSci, a fast growing, adaptable and award-winning contract research organisation (CRO), has highlighted its end-to-end services with an additional focus on lead optimisation. This expanded offering will allow CatSci to play a significant role in drug discovery and development, as the streamlined approach enables assets to move more efficiently through the pipeline.
Wickham Laboratories Ltd is delighted to announce our most recent technical article on, “Microbiological Considerations in Cleanroom Validation”, which has been featured in European Pharmaceutical Review’s December 2018 issue.
OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.